Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma

被引：7

作者：

Qin, Shu-Kui ^{[1
]}

Jin, Jie ^{[2
]}

Guo, Jun ^{[3
]}

Wang, Jin-Wan ^{[4
,5
]}

Zhou, Fang-Dian ^{[6
]}

Huang, Yi-Ran ^{[7
]}

Ren, Xiu-Bao ^{[8
]}

Ye, Ding-Wei ^{[9
]}

Pan, Sharon ^{[10
]}

Sajben, Peter ^{[10
]}

Wang, Qiao ^{[11
]}

机构：

[1] Nanjing Bayi Hosp, PLA Canc Ctr, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China

[2] Peking Univ, Hosp 1, Dept Urol, Beijing, Peoples R China

[3] Peking Univ, Canc Hosp & Inst, Dept Renal Canc & Melanoma, Beijing, Peoples R China

[4] Chinese Acad Med Sci, Canc Hosp Inst, Dept Med Oncol, Beijing, Peoples R China

[5] Peking Union Med Coll, Beijing, Peoples R China

[6] Sun Yat Sen Univ, Dept Urol, Canc Ctr, Guangzhou, Guangdong, Peoples R China

[7] Shanghai Renji Hosp, Dept Urol, Shanghai, Peoples R China

[8] Tianjin Med Univ, Canc Inst & Hosp, Dept Biol Treatment, Tianjin, Peoples R China

[9] Fudan Univ, Shanghai Canc Ctr, Dept Urol, Shanghai, Peoples R China

[10] Pfizer Inc, New York, NY 10017 USA

[11] Pfizer Global Res & Dev, Shanghai, Peoples R China

来源：

FUTURE ONCOLOGY | 2018年 / 14卷 / 18期

关键词：

Chinese; metastasis; renal cell carcinoma; sunitinib; targeted therapy; INTERFERON-ALPHA; PHASE-II; JAPANESE PATIENTS; SURVIVAL; HYPERTENSION; BIOMARKERS; SORAFENIB; AXITINIB; THERAPY;

D O I：

10.2217/fon-2017-0733

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: We report the first prospective study of sunitinib for metastatic renal cell carcinoma (mRCC) in China. Methods: Chinese mRCC patients received first-line sunitinib 50 mg daily (4/2 regimen). Overall survival (OS), progression-free survival (PFS), objective response rate and safety were assessed. Potential efficacy biomarkers were explored in post hoc analyses. Results: Median PFS was 61.7 weeks; median OS was 133.4 weeks; objective response rate was 31.1%. Most frequent adverse events (AEs) were: hand-foot syndrome (63.8%), decreased white blood cell count (52.4%), fatigue (51.4%) and decreased platelet count (51.4%). AEs were identified that predicted longer PFS and OS. Conclusion: Sunitinib showed efficacy and manageable AE profile in treatment-naive Chinese mRCC patients. Larger prospective studies are required to confirm identified AEs as predictors of efficacy.

引用

页码：1835 / 1845

页数：11

共 32 条

[1] Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma [J].

Akaza, Hideyuki ;

Tsukamoto, Taiji ;

Murai, Masaru ;

Nakajima, Keiko ;

Naito, Seiji .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (10) :755-762

[2] Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma [J].

Amzal, Billy ;

Fu, Shuai ;

Meng, Jie ;

Lister, Johanna ;

Karcher, Helene .

PLOS ONE, 2017, 12 (09)

[3]

[Anonymous], EUR MULT CANC C STOC

[4]

[Anonymous], 2011 ASCO ANN M CHIC

[5]

[Anonymous], 44 ANN M AM SOC CLIN

[6]

[Anonymous], 2013, GLOBOCAN 2012 V1 0

[7]

[Anonymous], 2011 EUR MULT CANC C

[8]

[Anonymous], NEW ENGL J MED

[9] A CONFIDENCE-INTERVAL FOR THE MEDIAN SURVIVAL-TIME [J].

BROOKMEYER, R ;

CROWLEY, J .

BIOMETRICS, 1982, 38 (01) :29-41

[10] Sunitinib: From rational design to clinical efficacy [J].

Chow, Laura Q. M. ;

Eckhardt, S. Gail .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) :884-896

← 1 2 3 4 →